What’s new in GOLD 2027?
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published its 2027 strategy report. The clearest change to the initial inhaler algorithm is a preference for a long-acting muscarinic antagonist (LAMA) in Group A. The report also recommends baseline chest CT where available, gives clinicians a more explicit approach to borderline spirometry and pre-COPD, and expands cardiovascular assessment, rehabilitation and integrated care.
| Clinical decision | What the 2027 report adds or changes |
|---|---|
| Confirming COPD | Retains the fixed post-bronchodilator threshold and adds guidance on discordant and borderline results. |
| Assessing early abnormalities | Refines pre-COPD, PRISm and COPD in younger adults, and gives examples of who may merit follow-up. |
| Imaging at diagnosis | Recommends noncontrast inspiratory and expiratory chest CT for the initial evaluation of patients with COPD where available. |
| Starting a Group A inhaler | Offer a LAMA first. A short-acting bronchodilator is a substitute if a LAMA is unavailable or unaffordable. |
| Managing exacerbations and recovery | Adds a figure on cardiovascular risk after moderate and severe events, with expanded guidance on investigating and treating comorbid cardiovascular disease. |
| Delivering non-drug care | Adds practical figures and checklists for pulmonary rehabilitation, exercise, physical activity, self-management and coordinated care. |
| Selecting biologics | Expands the evidence review. The clinical algorithm continues to position dupilumab and mepolizumab in selected patients with persistent exacerbations on triple therapy. |
1. Presentation and diagnosis: interpret spirometry in context
Suspect COPD when chronic breathlessness, cough, sputum or recurrent lower respiratory events occur alongside relevant exposures or risk factors. A history can include smoking, biomass smoke, occupational exposure and respiratory events early in life. Confirm persistent airflow obstruction with quality-assured post-bronchodilator FEV₁/FVC <0.70, interpreted in the clinical context. Persistent obstruction can also occur in asthma and other disorders.
The expanded spirometry section discusses the joint GOLD and Global Lung Function Initiative position. The fixed ratio is a practical diagnostic threshold. The lower limit of normal (LLN) accounts for how the ratio varies with age and can help resolve uncertainty. A fixed threshold may classify more older people and fewer younger people as having obstruction than the LLN does.
- Post-bronchodilator ratio 0.60–0.80: confirm on a separate occasion when interpreting a single result in this range. Review quality, symptoms and exposures and investigate discordance as indicated.
- Age under 50 with repeated ratio ≥0.70 but persistent suspicion: compare with the LLN or z-score and consider other lung function testing or specialist evaluation.
- Preserved ratio with symptoms: investigate the symptoms and consider structural or physiologic abnormalities and other diagnoses. A preserved ratio can coexist with respiratory disease.
GOLD expands its case for tracking spirometry across the life course. It proposes starting around age six and repeating at roughly three-year intervals through adolescence and early adulthood, with less frequent testing later if results remain normal. This is a proposed prevention strategy. Targeted case-finding in symptomatic and exposed people remains the immediate clinical approach.
2. Recognise pre-COPD and distinguish it from confirmed COPD
The revised terminology helps specify what is abnormal and who may need follow-up.
| Term | Clinical meaning in GOLD 2027 |
|---|---|
| Early COPD | A research concept referring to the early biological process. The timing of that process usually cannot be established in an individual patient. |
| Mild airflow obstruction | Describes spirometric severity. Record symptoms and exacerbations separately because their burden can be substantial. |
| COPD in younger adults | GOLD uses age under 50 as a practical definition. Consider early-life events, family history and impaired peak lung function alongside adult exposures. |
| Pre-COPD | At-risk individuals with symptoms, structural changes or physiologic abnormalities and a post-bronchodilator ratio ≥0.70. Progression varies. |
| PRISm | Preserved ratio impaired spirometry: post-bronchodilator FEV₁/FVC ≥0.70 with FEV₁ <80% predicted. It is a spirometric pattern that warrants evaluation in context. |
Examples in the new pre-COPD figure include CT emphysema, airway wall thickening, isolated reduction in diffusing capacity, chronic productive cough with relevant exposures, and excessive decline in FEV₁. A ratio above 0.70 but below the LLN, or obstruction before bronchodilation that resolves after it, can also prompt surveillance in the appropriate setting. Address modifiable exposures, investigate other causes of impairment and arrange follow-up spirometry when appropriate. Evidence for drug treatment of pre-COPD remains limited.
3. Use CT to characterise disease and guide the next decision
Where available, GOLD 2027 recommends noncontrast CT with inspiratory and expiratory images at initial COPD evaluation. GOLD 2026 focused on selected indications such as disproportionate symptoms, persistent exacerbations and intervention planning. Spirometry continues to establish airflow obstruction; CT can clarify which structural changes are present.
- Emphysema and gas trapping: assess distribution and severity. In patients with marked hyperinflation and suitable physiology, CT helps evaluate candidacy for lung volume reduction.
- Persistent exacerbations or breathlessness out of proportion to spirometry: reassess for contributors such as bronchiectasis, interstitial abnormalities or another diagnosis.
- Mucus plugging: GOLD discusses associations with adverse outcomes and its potential as a treatment target. Routine clinical scoring remains investigational.
- Incidental findings: coronary calcium, pulmonary artery enlargement or interstitial abnormalities may warrant separate assessment. Use the applicable lung cancer screening criteria to determine eligibility for annual low-dose CT.
Where access is limited, use the clinical question and the likelihood that imaging will change management to prioritise CT.
4. Start maintenance treatment with the ABE algorithm
For patients starting maintenance therapy, document symptom burden with CAAT or mMRC and count treated exacerbations over the preceding year. A CAAT score ≥10 identifies greater symptom burden; if using mMRC, grade ≥2 identifies greater breathlessness. GOLD 2026 already moved patients with one moderate exacerbation into Group E. GOLD 2027 retains that threshold.
| Initial group | GOLD 2027 starting treatment |
|---|---|
| A: lower symptoms, no moderate or severe exacerbations | Offer a LAMA. Substitute a short-acting bronchodilator if a LAMA is unavailable or unaffordable. |
| B: greater symptoms, no moderate or severe exacerbations | Start LABA plus LAMA if appropriate and accessible. If using one agent, individualise the choice according to symptom relief. |
| E: at least one moderate or severe exacerbation | Start LABA plus LAMA. Consider initial triple therapy with LABA plus LAMA plus inhaled corticosteroid (ICS) if blood eosinophils are ≥300 cells/µL. |
The Group A change specifies the drug class. GOLD 2026 allowed either short- or long-acting bronchodilation and generally preferred a long-acting agent except with very occasional breathlessness. The report acknowledges limited direct trial evidence for initial treatment algorithms in newly diagnosed patients. When asthma coexists, follow asthma guidance and include ICS. Ensure patients have a rescue bronchodilator for immediate symptom relief.
Follow-up: adjust according to breathlessness or exacerbations
Check adherence, inhaler technique, device suitability and additional causes of breathlessness before escalating. Persistent breathlessness on one long-acting agent generally leads to dual bronchodilation. If breathlessness persists, reconsider the device or drugs, investigate other causes and review rehabilitation needs.
When a moderate or severe exacerbation occurs on LABA plus LAMA, the report suggests adding ICS. Benefit is more likely from around 100 eosinophils/µL, with greater benefit at higher counts. This follow-up threshold serves a different decision from the ≥300 cells/µL threshold used when considering initial triple therapy in Group E. Weigh potential benefit against pneumonia and other adverse effects.
5. Persistent exacerbations: use phenotype to guide add-on therapy
Confirm that events are exacerbations and check technique, adherence and treatable contributors before adding a specialist therapy.
| Profile despite optimised therapy | Option described by GOLD |
|---|---|
| Persistent exacerbations on triple therapy, eosinophils ≥300 cells/µL and chronic bronchitis | Consider dupilumab. |
| Persistent exacerbations on triple therapy, eosinophils ≥300 cells/µL, with or without chronic bronchitis | Consider mepolizumab. |
| FEV₁ <50% predicted, chronic bronchitis and a prior severe exacerbation | Consider roflumilast. |
| Persistent exacerbations in a person who is not currently smoking | Consider azithromycin in an appropriate patient, taking antimicrobial resistance and adverse effects into account. |
The expanded biologics section also reviews benralizumab, astegolimab and tozorakimab. Benralizumab trials did not show a lower annualised exacerbation rate. Astegolimab showed mixed results across studies. GOLD reports fewer moderate or severe events with tozorakimab in studied patients, including across eosinophil categories. These findings belong to the evidence review; the follow-up algorithm names dupilumab and mepolizumab. Check the applicable indication and access criteria before prescribing either.
6. Put rehabilitation and prevention into the care plan
The expanded non-drug chapter distinguishes pulmonary rehabilitation, a coordinated programme with assessment, prescribed exercise, education and self-management, from exercise training, which improves physical capacity, and physical activity coaching, which helps patients move more in everyday life. The updated figures help match each intervention to the patient’s goals and barriers.
Refer symptomatic or exercise-limited patients and reassess the need for referral after an exacerbation or hospital admission. GOLD describes programmes commonly lasting six to twelve weeks with at least two supervised sessions weekly. Tailor the setting and intensity to function, comorbidities and access. At follow-up, review breathlessness, exercise capacity, daily activity and what the patient can sustain.
Include smoking cessation and exposure reduction, inhaler teaching and teach-back, a written exacerbation plan with ongoing support, and review of vaccination under local schedules. GOLD updates its review of influenza, pneumococcal, RSV and COVID-19 vaccination and also discusses pertussis and zoster. Apply local age and risk criteria, vaccine availability and prior immunisation history. The report also discusses lower global warming potential propellants in certain metered-dose inhalers. Ensure that the selected device can reliably deliver the prescribed medication for the patient.
7. Take cardiovascular risk seriously during and after exacerbations
The revised chapters add figures on the risk of cardiovascular events after moderate and severe COPD exacerbations and on managing coexisting cardiovascular disease. Observational data show elevated risk of myocardial infarction, heart failure, arrhythmia and stroke, particularly in the weeks after a severe exacerbation. Elevated risk may persist for up to a year.
- During acute deterioration: assess for heart failure, acute coronary syndrome and arrhythmia when the history, examination or course raises suspicion. Consider other mimics such as pneumonia and pulmonary embolism.
- Testing: use ECG and cardiac biomarkers as clinically indicated. GOLD discusses broader use of troponin and natriuretic peptides during exacerbations, with weak evidence for routine testing. Investigate abnormal findings in context.
- After discharge: arrange follow-up that explicitly reviews cardiovascular symptoms, risk factors and prevention. Treat hypertension, coronary disease, heart failure and atrial fibrillation according to their respective guidelines. A COPD exacerbation alone does not establish an indication for aspirin, a statin or a beta-blocker.
8. Use the new checklists to structure reviews
The new pharmacological and non-pharmacological checklists (Appendices 2 and 3) can be used at diagnosis and during follow-up. Record whether spirometry confirmed the diagnosis, the symptom score and exacerbation history, the inhaler regimen and technique, exposure reduction, vaccinations, rehabilitation and the plan for comorbidities. Add a clear follow-up date and the outcomes that will guide treatment changes.
GOLD’s new shared section with GINA sets out common priorities for asthma and COPD, including access to diagnostic testing and effective inhaled treatment. Its new AI figure maps potential uses in diagnosis, assessment and follow-up. Evidence for specific tools, implementation and virtual care delivery continues to evolve.
Sources
1. GOLD 2027 full strategy report, final revision dated 15 November 2026 2. GOLD 2027 official summary of changes 3. GOLD 2026 strategy report, used for comparison
